PSORIASIS:
<One notable omission from your list is MEDI-507 entering Ph1 for psoriasis in 4/99.>
So here's how the thread is supposed to work... you put the header up there, so everyone sees the indication you're updating, and people don't have to schag through lots of posts to find what they're looking for. Then you're message and what you're doing [this dibble I've written] then copy the last indication you saw on the thread and make your addition:
Indication: Psoriasis
Market: Small, Moderate, Giant
Approved competition: Weak, Moderate, Strong
Clinical [pre-clinic?] competition:
Ligands's *retins, and Ontak, Ph?
Abgenix anti-IL8 human antibody Ph?
ICOS's anti-ICAM-3 antibody
Vertex small molecule inhibitor of T-cell proliferation
Axys tryptase small molecule inhibitor
IDEC's anti-B7 and (maybe??) anti-CD4 antibodies ...
Biogen's Amevive, phIIb
Xoma Hu1124, Anti-CD11a antibody, Ph2
ISIS 2302 (ICAM-1 inhibitor)
MEDI-507 [new PH1, 4/99] also in ph2 for organ rejection.
Worthwhile links:
Message 10418030
recap.com
Then the next person does the same and on and on... this way we have updated info... commentary on each would be a bonus also.. notice I'm hoping someone jump in and fill in market size for the indications, etc...
DAK
DAK |
